TABLE 2.

Summary of the incidence of cardiac diseases caused by PD-1/PD-L1 inhibitors (ICIs).

Toxicity	Authors	Incidence
Myocarditis	Mir et al. (2018)	40.20% a
	Rubio-Infante et al. (2021)	18.84% b
	Barlesi et al. (2018)	1.05% c
	Rubio-Infante et al. (2021)	0.72% d
	Salem et al. (2018)	0.50% c
	Jain et al. (2021)	0.05% e
Pericardial disease or tamponade	Mir et al. (2018)	15.28% a
	Rubio-Infante et al. (2021)	2.12% b
	Salem et al. (2018)	0.36% c
Vasculitis	Salem et al. (2018)	0.28% c
Cardiomyopathy	Mir et al. (2018)	31.94% a
Congestive heart failure
	Rubio-Infante et al. (2021)	0.04% d
Atrial fibrillation	Rubio-Infante et al. (2021)	11.54% b
	Jain et al. (2021)	1.92% e
	Antonia et al. (2017)	0.84% c
	Rubio-Infante et al. (2021)	0.06% d
Heart failure	Rubio-Infante et al. (2021)	8.45% b
	Jain et al. (2021)	3.56% e
	Barlesi et al. (2018)	1.05% c
	Salem et al. (2018)	0.72% f
	Rubio-Infante et al. (2021)	0.15% d
	Socinski et al. (2018)	0.25% c
Pericardial effusion	Rubio-Infante et al. (2021)	8.14% b
	Antonia et al. (2017)	0.42% c
	Rubio-Infante et al., 2021)	0.15% d
Tachycardia	Rubio-Infante et al. (2021)	6.60% b
	Antonia et al. (2017)	0.21% c
Myocardial infarction	Rubio-Infante et al. (2021)	6.55%b
	Jain et al. (2021)	0.90%e
	Salem et al. (2018)	0.53% f
	Antonia et al. (2017)	0.42% c
	Socinski et al. (2018)	0.25% c
Cardiac arrest	Rubio-Infante et al. (2021)	5.40%b
	Rubio-Infante et al. (2021)	0.02%d
Cardiac death or shock	Salem et al. (2018)	0.43% f
	Antonia et al. (2017)	0.21% c
Sinus tachycardia	Rubio-Infante et al. (2021)	2.23%b
Pericarditis	Rubio-Infante et al. (2021)	3.37%b
Arrhythmia	Rubio-Infante et al. (2021)	2.59%b
	Salem et al. (2018)	0.07% f
Cardiac supra-ventricular arrhythmias	Salem et al. (2018)	0.71% f
Atrioventricular block	Horn et al. (2018)	0.50% c
	Rubio-Infante et al. (2021)	0.04% d
Cardiac conductive disorders	Jain et al. (2021)	1.46% e
	Salem et al. (2018)	0.12% f
Endocardial disorders	Salem et al. (2018)	0.03% f
Cardiac valve disorders	Salem et al. (2018)	0.02% f
Hypertension	Socinski et al. (2018)	19.10% c
	Barlesi et al. (2018)	4.20% c
	Robert et al. (2015)	0.72% c
	Antonia et al. (2017)	0.21% c
Stroke	Jain et al. (2021)	3.71% e

^aIncidence of disease in the patients with cardiac disease caused by PD-1/PD-L1 inhibitors.

^bIncidence of disease in the patients with cardiac diseases caused by PD-1/PD-L1 inhibitors (data retrieved from the VigiAccess database).

^cIncidence of disease in the patients using PD-1/PD-L1 inhibitors.

^dIncidence of disease in the patients using ICI inhibitors (data retrieved from meta-analysis).

^eIncidence of disease in the patients with cardiac diseases caused by PD-1/PD-L1 inhibitors (data retrieved from the International Business Machines (IBM) MarketScan Research Databases).

^fIncidence of disease in the patients using ICI inhibitors (the proportion of CTLA4 inhibitors is 26.4%).